Ralaniten (developmental code name EPI-002) is an N-terminal domain antiandrogen which was never marketed.[1] It is a derivative of bisphenol A[2] and one of the four stereoisomers of EPI-001.[1] A prodrug of ralaniten, ralaniten acetate (EPI-506), was under development for the treatment of prostate cancer.[3]
Clinical data | |
---|---|
Other names | EPI-002 |
Drug class | Nonsteroidal antiandrogen |
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
ChemSpider |
|
UNII |
|
KEGG |
|
Chemical and physical data | |
Formula | C21H27ClO5 |
Molar mass | 394.89 g·mol−1 |
3D model (JSmol) |
|
| |
|